Abstract:
We delineate a KMT2E gene-related neurodevelopmental disorder based on 38 individuals in 36 families. This includes 31 distinct heterozygous variants in the KMT2E gene (28 ascertained from Matchmaker Exchange and 3 previously reported), and 4 individuals with chromosome 7q22. .23 microdeletions encompassing the KMT2E gene (1 previously reported). Almost all variants occurred de novo, and most were truncating. Most affected individuals with protein-truncating variants presented with mild intellectual disability. One-quarter of individuals met criteria for autism. Additional common features include macrocephaly, hypotonia, functional gastrointestinal abnormalities, and a subtle facial gestalt. Epilepsy was present in about one-fifth of individuals with truncating variants, and was responsive to treatment with anti-epileptic medications in almost all. Over 70% of the individuals were male and expressivity was variable by sex, with epilepsy more common in females and autism more common in males. The four individuals with microdeletions encompassing KMT2E generally presented similarly to those with truncating variants, but the degree of developmental delay was greater. The group of four individuals with missense variants in KMT2E presented with the most severe developmental delays. Epilepsy was present in all individuals with missense variants, often manifesting as treatment-resistant infantile epileptic encephalopathy. Microcephaly was also common in this group. Haploinsufficiency versus gain-of-function or dominant negative effects specific to these missense variants in KMT2E may explain this divergence in phenotype, but requires independent validation. Disruptive variants in KMT2E are an under-recognized cause of neurodevelopmental abnormalities.
Main Text
KMT2E encodes a member of the lysine N-methyltransferase 2 (KMT2) family. This family of enzymes plays a vital role in regulating post-translational histone methylation of histone 3 on lysine 4 (H3K4) 1 . Proper H3K4 methylation is required to maintain open chromatin states for regulation of transcription. There are at least eight known monogenic disorders impairing regulation of H3K4 methylation that present with neurodevelopmental syndromes (Table 1 ). In addition to these Mendelian disorders, dysregulated H3K4 methylation is believed to play a role in the pathogenesis of schizophrenia and autism 2 . De novo truncating variants in the KMT2E gene have previously been reported in three unrelated males in a large sequencing study of nonsyndromic autism, but phenotypic data was limited [3] [4] [5] . In this report, we present twentynine additional individuals with heterozygous variants in KMT2E in an effort to define a KMT2E-related neurodevelopmental disorder. We also describe four individuals with chromosome 7q22.2-22.23 microdeletions encompassing KMT2E. New cases were ascertained from GeneMatcher through the Matchmaker Exchange Network between September 2016 and August 2018 6, 7 . All individuals were found to have variants in KMT2E on exome or genome sequencing. Informed consent was obtained for photographic images used in composite figure generation.
KMT2E is constrained for protein-truncating variation in the general population
The Genome Aggregation Database (gnomAD) is a large-scale reference database with high quality, jointly processed exome or genome data from over 140,000 individuals 8 . Constraint analysis performed on the gnomAD dataset shows that KMT2E is a candidate haploinsufficient gene. KMT2E is very depleted for protein-truncating variants presumably due to negative selection, with an observed/expected ratio of 0.01 and probability of loss of function intolerance (pLI) score of 1.0.
We reviewed the 28 loss of function variants present in gnomAD v2.1. The majority of these variants are not expected to result in protein truncation for a variety of reasons including annotation artifacts (n=8), sequence errors at a simple repeat (n=5), somatic mosaicism (n=1), and a splice site rescue (n=1). Four variants are part of a complex variant in one individual that when resolved, is not expected to result in truncation. Four variants found in eight individuals in gnomAD are in the last exon; two are expected to result in truncation of the last exon and two will result in protein extension. Of note, the two protein-extension variants are located close to the variant in individual #28 (p.Val1818Alafs*48). The inheritance of this variant is unknown as the father is not available for testing, though it is not present in his mother, so this remains a variant of uncertain significance.
After review, there were five variants in gnomAD that appear to result in protein truncation. These are found in 3 males and 2 females between the ages of 30 and 70. All 5 are absent from the control only subset of gnomAD (though it should be noted that gnomAD does not contain cohorts recruited for severe, pediatric onset disease, rather contains cohorts recruited for adult onset common diseases such as cardiovascular disease and type II diabetes). By reviewing the data subsets, two appear to be from neurologic cohorts and three are from non-neuro and non-cancer cohorts. Overall, there are very few variants that are likely to result in protein truncation of KMT2E present in a large general population reference database.
We ascertained thirty-eight individuals with KMT2E gene variants in association with a neurodevelopmental phenotype
Including the three previously reported cases [3] [4] [5] , thirty-four individuals from thirty-two families were ascertained with single nucleotide or indel variants in KMT2E and four additional individuals had copy number variants encompassing KMT2E ( Figure 1 , Table  2 ). The KMT2E variants were found to have arisen de novo in 26 individuals in our cohort. The variant was maternally-inherited in one of the previously reported individuals (maternal phenotype unknown) 5 . Inheritance of the variant was unknown in four families where both parents were not available for testing. In only one family was the variant found in multiple affected individuals with three affected male children; the variant was not found in their mother, and the father was not available for testing, but he was reported to have intellectual disability. Thirty variants were protein-truncating variants: twenty-four were indels, four were nonsense variants, and two were variants at essential splice sites ( Figure 1A ). Twenty-three of these are predicted to produce transcripts that would be subject to nonsense mediated decay. Five of the proteintruncating variants fall in the terminal exon of the gene, potentially escaping nonsensemediated decay; three of these five variants extend the open reading frame. Only one variant was seen in two independent families (c.1776_1780delAAAGA, p.Lys593Argfs*17) in a male (individual #9) and a female (individual #10). Four of the individuals had de novo missense variants, three of which occur at highly conserved positions/regions of the gene (P1376S is not well conserved and serine is present in some mammalian species) ( Figure 1B ). There was no particular patterning or clustering of the missense variants. CADD scores are summarized in Table 2 . None of the KMT2E variants are reported in public databases (gnomAD, Exome Variant Server, or 1000 Genomes) [8] [9] [10] . Figure 1C illustrates the genes included in these deletions. Median maternal and paternal age was 30 and 36 years, respectively. There were phenotypic differences between individuals with protein-truncating variants, missense and copy number variants, as summarized below.
Thirty-four individuals with KMT2E Protein-truncating variants:
For the individuals with protein-truncating variants in KMT2E, 22 were male and eight were female. Age at most recent evaluation ranged from 19 months to 24 years. Prenatal and neonatal courses were largely uncomplicated for most individuals with protein-truncating variants. One individual was born prematurely at 35 weeks. Several individuals had neonatal jaundice, one had hypoglycemia, one had sinus tachycardia, and two had neonatal feeding difficulties. Individual #10 developed respiratory arrest at fourteen hours of life and had a hypoxic-ischemic injury with typical sequelae seen on neuroimaging. She has spastic quadriplegia and epilepsy, and is not included in the subsequent paragraphs below since her acquired injury significantly influences her phenotype and is likely not representative of the disorder itself (although it cannot be excluded that the genetic disorder predisposed to the injury).
Of the remaining 29 individuals in this group (i.e. excluding individual #10), 24 had early developmental delay. The three individuals without documented developmental delay are the cases previously reported from autism studies where only limited clinical information is available [3] [4] [5] . The mean age of independent walking in this group was 20 months (range 12-48 months, Figure 2 ). All individuals are currently able to walk independently. Twelve of the 29 individuals have hypotonia. Individual #15 had normal initial motor development, but developed progressive spastic diplegia at 14 months of age. Neuroimaging in this individual demonstrated cerebral white matter abnormalities.
Figure 2: Developmental milestones in individuals with variants in KMT2E
Most children with protein-truncating variants acquire first words and walking by 24 months of age, though a minority are more significantly delayed. Only individual #12 who experienced a cardiac arrest and injury did not acquire these skills. A majority of individuals with microdeletion had significant delay in speech development but walked at a similar time to individuals with protein-truncating variants. For those with missense variants, those with severe infantile epilepsy had significant delays.
The mean age of acquired first word in this group was 20 months (range 12-48 months, Figure 2 ). Though this information is not available for all individuals, 14 (out of 17) individuals are verbal, though seven are noted to speak poorly or have articulation problems. Three of the individuals were reported to have speech regression. Intelligence quotient (IQ) data were available for only seven out of the 29 individuals: the mean IQ was 74 (range 62-98). Seven of the individuals have been diagnosed with autism. One additional individual was diagnosed with a sensory integration disorder, and another with difficulty in social interaction not meeting criteria for autism. At least two of the individuals have been diagnosed with attention-deficit/hyperactivity disorder (ADHD). Additional behavioral concerns were reported in eleven of the individuals, including stereotypies, skin picking behavior, self-injurious behavior, aggression, and anxiety.
Fourteen of the 30 individuals had macrocephaly, defined by a head circumference equal to two or more standard deviations above the mean, or 95th percentile or greater. An additional two individuals have relative macrocephaly, defined here as head circumference one standard deviation higher than the standard deviation for the height. Individual #6 also had a de novo pathogenic PTEN variant, which can also account for his macrocephaly. Other growth parameters were variable for individuals in this group, but most were in the normal range for height and weight.
Excluding individual #10 with hypoxic-ischemic injury, only four of the individuals in this group had epilepsy (two or more unprovoked seizures) (#4, #7, #8, #22); an additional patient had a history of just one seizure at eight years of age (#9). There was no consistent seizure semiology or epilepsy syndrome described across the individuals. Only one of the four individuals with epilepsy had treatment-resistant epilepsy (#7). Nineteen of the individuals had at least one brain MRI. MRI findings were normal or non-specific, with no consistent abnormalities. Thinning or partial agenesis of the corpus callosum (individuals #5, #12, #15), various cysts including pineal, epidermoid, arachnoid, ependymal (in individuals #6, #7, #8, #19, respectively), increased white matter signal (individual #8, #17), hyperintense signal in the basal ganglia (individual #10), decreased volume (individuals #5, #10, #12, #15), delayed myelination (individual #19), small areas of heterotopia (individual #20) and Chiari I malformation (individual #14).
Many of the individuals were reported to have gastrointestinal symptoms, including reflux, vomiting, or bowel motility issues; these are issues commonly seen in individuals with hypotonia. All individuals tested had normal hearing. There were no significant ophthalmological findings. There were no other recurrent health complications noted in this group. Comparing individuals with truncating variants in the terminal exon of KMT2E to those with earlier truncating variants, there were no clear phenotypic differences, though the number of individuals available for comparison is small.
It is notable that 22 out of the 30 individuals with protein-truncating variants were male. Additionally, the expressivity of certain aspects of the phenotype is variable between males and females (Table 3) . While the rate of intellectual disability and macrocephaly were consistent, interestingly, epilepsy was seen in 43% of females and in only 5% of males (p=0.04, Fisher's Exact test), while autism was seen in 35% of males and in none of the females (p=0.14, Fisher's Exact test) with protein-truncating variants in KMT2E. It is possible that there is decreased penetrance or variable expressivity of the condition in females, leading to fewer female individuals with de novo protein-truncating variants coming to diagnostic attention. 
Four individuals with 7q22.2-22.3 chromosome deletions involving KMT2E:
For the four individuals with de novo copy number variants including KMT2E, two were male and two were female. Age at most recent evaluation ranged from 7 to 22 years. Clinically, patients with deletions presented similarly to those with truncating variants.
While the sample size is small, there appear to be more severe developmental delays in this group. Average age of first words was 34.5 months (range 18 to 48 months, Figure  2 ). Only two of the four individuals are verbal. Walking was delayed in all, with a range of 15-42 months. Three of the four individuals in this group have epilepsy (#30, #31, #32). Two of the four individuals in this group have macrocephaly (#29, #32).
Individual #32 has been previously reported 12 . He presented with global developmental delay, overgrowth, macrocephaly, delayed bone age, and treatment refractory generalized epilepsy. MRI of the brain demonstrated reduction of cerebral white matter, corpus callosum hypoplasia, right cerebellar hypoplasia, and an enlarged cisterna magna. Brain imaging was also performed in individuals #30 and #31. The MRI of individual #31 demonstrated global cerebral atrophy, and the MRI of individual #30 demonstrated a possible focal cortical dysplasia.
Four individuals with de novo KMT2E missense variants:
For the four individuals with de novo missense variants in KMT2E, two were male and two were female. Age at most recent evaluation ranged from 29 months to 36 years. All four of the individuals with missense variants had epilepsy. Individual #33 had five generalized tonic-clonic seizures, starting at the age of 15 years. Individuals #34, #35, and #36 all presented with infantile epileptic encephalopathy. Individual #34 developed seizures at 6 months of age, and individuals #35 and #36 both developed seizures in the neonatal period. Reported seizure semiologies include generalized tonic-clonic, tonic, atonic, myoclonic seizures, and epileptic spasms. The initial EEG in individual #35 showed burst-suppression, and subsequently evolved into hypsarrhythmia. The EEG in individual #36 also showed hypsarrhythmia. The EEG in patient #34 demonstrated background disorganization, and multifocal and generalized epileptiform discharges. All three individuals have treatment-resistant epilepsy. Individual #34 was started on the ketogenic diet at 14 months of age, which did not improve seizure control.
In our cohort, individuals with missense variants also had more severe developmental delays compared to the individuals with truncating variants. Only two of the four individuals can walk independently, and none of the individuals are verbal at most recent follow-up (Figure 2) . Two of the four individuals in this category have microcephaly, and the other two are normocephalic. Three of these individuals had a brain MRI: one individual had delayed myelination, one had cerebral atrophy, and one had an incidental abnormality in the right cerebral peduncle.
Facial analysis
Comparison of the facial features of eleven of the individuals in our cohort suggests some commonalities, including macrocephaly, dolichocephaly, high forehead, deep-set eyes, periorbital fullness, prominent cheeks, and prominent nasolabial folds (Figure 3 ). Utilizing Face2Gene (FDNA, Inc., Boston, MA) facial recognition software, we created a composite image from frontal photographs of these 11 individuals (excluding individual #30 with glasses) to represent the common facial gestalt. KMT2E encodes a histone methyltransferase protein, a transcriptional regulator reported to play key roles in diverse biological processes, including cell cycle progression, maintenance of genomic stability, adult hematopoiesis, and spermatogenesis. The gene is highly expressed in the brain, particularly during fetal development 4 . KMT2E appears to be distinct from other members of the KMT2 family. Most KMT2 proteins contain an enzymatically active SET domain that possesses methyltransferase function 2, 13 . While the KMT2E protein contains a SET domain, it is different in sequence and location within the protein than other members of the KMT2 family, and studies suggest that it may lack intrinsic methyltransferase activity 14 . However, the SET domain is still highly conserved in KMT2E, and it has been proposed that KMT2E may have an indirect effect on H3K4 methylation, possibly through transcriptional regulation of additional histone modifying enzymes. Most members of the KMT2 family contain multiple PHD finger domains that function as H3K4 methylation readers. In contrast, KMT2E contains a single PHD finger domain. PHD fingers typically bind to specific epigenetic histone marks in order to recruit transcription factors and nucleosome-associated complexes to chromatin. Finally, while most members of the KMT2 family function as global activators of open chromatin, KMT2E is believed to be a repressor, although the precise mechanisms involved in KMT2E regulation of gene transcription have not yet been elucidated 15 .
The individuals with protein-truncating KMT2E variants in our cohort present with syndromic intellectual disability. Most individuals are functioning in the low-normal to mild intellectual disability range. Seven of the individuals (including of the three previously reported individuals [3] [4] [5] ) have also been formally diagnosed with autism. There appears to be a subtle common facial gestalt amongst the individuals whose images were available for review. Additional features, albeit not obligate or specific, include macrocephaly, hypotonia, and GI dysmotility. Neuroimaging is normal or nonspecific. Epilepsy was not common among the individuals with protein-truncating variants. There were no significant phenotypic differences between individuals with truncating variants in the terminal exon of the gene and earlier truncating variants, suggesting a probable common pathophysiology of haploinsufficiency.
In contrast to the individuals with protein-truncating variants, the individuals we report with missense variants all have epilepsy. Three of these individuals fall in the category of an infantile-onset epileptic encephalopathy. In addition, these individuals have more severe developmental delays, and two have microcephaly. We hypothesize that the phenotype of epileptic encephalopathy may be variant specific, and may relate to an alternate mechanism such as gain-of-function or dominant negative effect. Recently distinct developmental disorder phenotypes have been identified to result from PTVs and missense variants in the same gene 16, 17 . Additional cases and further functional studies are required to clarify this.
Overall, the individuals with chromosome 7q22.2-22.3 microdeletions encompassing KMT2E presented similarly to those with truncating variants, further supporting haploinsufficiency as the disease mechanism. While the sample size was small, these individuals appeared to have more severe developmental delays compared to those individuals with truncating variants, which is likely explained by the influence of additional genes included in their deletions. The 7q22.2-22.3 region contains multiple additional genes involved in the regulation of the cell cycle, including SRPK2, RINT1, and LHFPL3 12 . In particular, the SRPK2 gene is also high constrained in the gnomAD database (pLI of 1.0) and is expressed in the central nervous system. The SRPK2 gene encodes a cell-cycle regulated protein kinase that phosphorylates serine/arginine domain-containing proteins and modulates pre-mRNA splicing in neurons 18 .
Several Kmt2e (Mll5) deficiency mouse models have been created and characterized 15, [19] [20] [21] [22] . These mice present with growth restriction and increased mortality, as well as impaired hematopoiesis. A neurological phenotype in these mice has not been reported. Both homozygous and heterozygous loss of Kmt2e in mice results in DNA damage and elevated levels of reactive oxygen species (ROS) 22 . The cellular effects were effectively reversed by supplementation with the glutathione precursor, Nacetylcysteine (NAC) 22 . This has interesting therapeutic implications in humans, since NAC supplementation has been used to treat glutathione depletion in acetaminophen overdose as well as rare inborn errors of metabolism associated with increased free radical damage. Further studies are required to establish whether humans haploinsufficient for KMT2E are also vulnerable to increased ROS, and whether there may be a benefit in treating with NAC or other antioxidants.
In this report, we define a KMT2E-related neurodevelopmental disorder, which adds to the growing list of KMT2 gene family disorders. Most individuals with protein-truncating variants appear to present with generally mild developmental delay/intellectual disability. Autism is also relatively common. Additional common, but not obligate, features include relative macrocephaly, hypotonia, and functional gastrointestinal disturbances. There appears to be a subtle facial gestalt. Epilepsy was not common amongst individuals with protein-truncating variants. We suspect haploinsufficiency as the disease mechanism. The similar phenotype seen in individuals with microdeletions of this region is consistent with this hypothesis. In contrast, individuals with missense variants all presented with epilepsy, including infantile-onset epileptic encephalopathy, and more severe developmental delays. Variant specific alterations in KMT2E function, possibly even gain-of-function, may explain this divergence in phenotype. Further studies are required to further understand genotype-phenotype correlation. There is no established therapy for KMT2E-related disorders, although based on animal data, there may be a role for N-acetylcysteine or other antioxidant treatments.
